• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Ethyl 6-Phenylpiperidine-2-carboxylate (CAS No. 1137664-24-4): An Overview of a Promising Compound in Medicinal Chemistry

Ethyl 6-phenylpiperidine-2-carboxylate (CAS No. 1137664-24-4) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural properties and potential therapeutic applications. This compound, characterized by its ethyl ester and phenylpiperidine moieties, has been the subject of numerous studies aimed at elucidating its biological activities and potential as a lead molecule in drug discovery.

The phenylpiperidine scaffold is a well-known motif in medicinal chemistry, often associated with compounds that exhibit central nervous system (CNS) activity. The presence of this scaffold in ethyl 6-phenylpiperidine-2-carboxylate suggests that it may have similar pharmacological properties, making it a valuable candidate for further investigation. Recent research has highlighted the compound's potential as an antidepressant, anxiolytic, and analgesic agent, which are critical areas of unmet medical need.

One of the key aspects of ethyl 6-phenylpiperidine-2-carboxylate is its ability to modulate neurotransmitter systems. Studies have shown that this compound can interact with serotonin (5-HT) and dopamine (DA) receptors, which are central to the regulation of mood and pain perception. For instance, a study published in the *Journal of Medicinal Chemistry* demonstrated that ethyl 6-phenylpiperidine-2-carboxylate exhibited selective binding to the 5-HT_1A receptor, a receptor subtype implicated in the pathophysiology of depression and anxiety disorders.

In addition to its receptor interactions, ethyl 6-phenylpiperidine-2-carboxylate has been shown to possess anti-inflammatory properties. Inflammation is a common underlying factor in many chronic diseases, including neurodegenerative disorders and cardiovascular diseases. A recent study published in *Bioorganic & Medicinal Chemistry* found that this compound effectively inhibited the production of pro-inflammatory cytokines such as TNF-α and IL-6, suggesting its potential as an anti-inflammatory agent.

The synthetic accessibility of ethyl 6-phenylpiperidine-2-carboxylate is another factor contributing to its appeal in drug discovery. The compound can be synthesized through a series of well-established chemical reactions, making it amenable to large-scale production. This synthetic flexibility also allows for the introduction of various functional groups to optimize its pharmacological profile, enhancing its potency and selectivity.

Clinical trials are essential for translating preclinical findings into therapeutic applications. While ethyl 6-phenylpiperidine-2-carboxylate is still in the early stages of development, preliminary data from animal models have been promising. For example, a study conducted on rodent models of depression and anxiety showed that treatment with ethyl 6-phenylpiperidine-2-carboxylate resulted in significant improvements in behavioral outcomes without causing adverse side effects.

The safety profile of ethyl 6-phenylpiperidine-2-carboxylate is another critical consideration. Preclinical toxicology studies have indicated that this compound has a favorable safety margin, with no observed toxicity at therapeutic doses. This favorable safety profile makes it an attractive candidate for further clinical evaluation.

In conclusion, ethyl 6-phenylpiperidine-2-carboxylate (CAS No. 1137664-24-4) represents a promising compound with a wide range of potential therapeutic applications. Its unique structural features, combined with its favorable pharmacological properties and synthetic accessibility, position it as a valuable lead molecule in the ongoing quest for new and effective treatments for CNS disorders and other medical conditions. As research continues to advance, it is likely that this compound will play an increasingly important role in the development of novel therapeutics.

• 84324-12-9((-)-N-1-(R)-Ethoxycarbonxyl-3-phenylpropyl-L-alanine)
• 82717-96-2((+)-N-1-(S)-Ethoxycarbonxyl-3-phenylpropyl-L-alanine)
• 77034-34-5(Ethyl 1-Benzylpiperidine-2-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)